{
    "clinical_study": {
        "@rank": "82151", 
        "acronym": "SIGN", 
        "arm_group": [
            {
                "arm_group_label": "CGM - intervention arm", 
                "arm_group_type": "Experimental", 
                "description": "Following a 14 day masked (baseline) period using the FreeStyle Navigator subjects will wear an unmasked FreeStyle Navigator."
            }, 
            {
                "arm_group_label": "SMBG - Control arm", 
                "arm_group_type": "Active Comparator", 
                "description": "Following a 14 day masked ( baseline) period using the FreeStyle Navigator subjects will manage their blood glucose with a standard SMBG and use a FreeStyle Navigator masked for a 14 day period at the end of the study."
            }
        ], 
        "brief_summary": {
            "textblock": "To understand if Multiple Daily Injections (MDI) managed subjects can improve glycaemic\n      control by;\n\n        1. regularly checking and understanding Continuous Glucose data & trend arrows at times\n           other than the standard pre-meal bolus calculation test times and\n\n        2. review of their glucose profiles (inc. hypoglycaemic risks) with their HCP and\n           adjusting behaviours & therapy from interpretation of the Continuous Glucose profiles."
        }, 
        "brief_title": "Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 years and over\n\n          -  Type 1 diabetes on MDI  with bolus injections for >6 months prior to study enrolment\n             or Type 2 diabetes treated with 2 or more insulin injections daily.\n\n          -  In the investigator's opinion, thought technically capable of using FreeStyle\n             Navigator GM System device.\n\n          -  HbA1c between 7.5 and 12.0% (58 to 108 mmol/mol) for previous test obtained within 6\n             months prior to point of enrolment\n\n        Exclusion Criteria:\n\n          -  Concomitant disease or condition that may compromise patient safety, including\n             unstable coronary heart disease, cystic fibrosis, serious psychiatric disorder, or\n             any uncontrolled chronic medical condition\n\n          -  Female subject is pregnant or planning to become pregnant within the planned study\n             duration. Subjects who become pregnant during the study will be discontinued from the\n             study.\n\n          -  Currently using / has previously used a Continuous Glucose Monitoring System within\n             the last 6 months.\n\n          -  Currently using Continuous Subcutaneous Insulin Infusion (CSII)\n\n          -  Currently using basal/long acting insulin only.\n\n          -  Participating in another study of a glucose monitoring device / drug that could\n             affect glucose measurements / management\n\n          -  Known allergy to medical grade adhesives\n\n          -  In the investigators opinion is unsuitable to participate due to any other\n             cause/reason."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01713348", 
            "org_study_id": "ADC-PMR-APO-12015"
        }, 
        "intervention": [
            {
                "arm_group_label": "CGM - intervention arm", 
                "description": "Masked CGM day 1 to 15, unmasked CGM days 15 to 100", 
                "intervention_name": "FreeStyle Navigator", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "SMBG - Control arm", 
                "description": "Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100", 
                "intervention_name": "Standard SMBG", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "CGM", 
            "MDI"
        ], 
        "lastchanged_date": "July 2, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ayr", 
                        "country": "United Kingdom", 
                        "state": "Ayrshire", 
                        "zip": "KA6 6DX"
                    }, 
                    "name": "Ayr Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ashton-under-Lyne", 
                        "country": "United Kingdom", 
                        "zip": "OL6 9RW"
                    }, 
                    "name": "Tameside Hospital NHS Foundation Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bath", 
                        "country": "United Kingdom", 
                        "zip": "BA1 3NG"
                    }, 
                    "name": "Royal United Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "City and Borough of Birmingham", 
                        "country": "United Kingdom", 
                        "zip": "B9 5SS"
                    }, 
                    "name": "Birmingham Heartlands Hospital, Diabetes Clinic"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United Kingdom", 
                        "zip": "DH1 5TW"
                    }, 
                    "name": "University Hospital of North Durham"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ipswich", 
                        "country": "United Kingdom", 
                        "zip": "IP4 5PD"
                    }, 
                    "name": "Ipswich Hospital NHS Trust"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leeds", 
                        "country": "United Kingdom", 
                        "zip": "LS9 7TF"
                    }, 
                    "name": "St James Hospital,"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotherham", 
                        "country": "United Kingdom", 
                        "zip": "S60 2UD"
                    }, 
                    "name": "Rotherham General Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wolverhampton,", 
                        "country": "United Kingdom", 
                        "zip": "WV10 0QP"
                    }, 
                    "name": "Diabetes Centre, New Cross Hospital,"
                }
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes", 
        "overall_official": {
            "affiliation": "St James Hospital, Leeds", 
            "last_name": "Ramzi Ajjan", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United Kingdom: Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Within subject difference in time in range (70-180 mg/dL, 3.9 to 10.0 mmol/L) in final 15 days compared to baseline phase assessed separately for T1/T2.", 
            "measure": "Time in range", 
            "safety_issue": "No", 
            "time_frame": "Day 86 to 100 compared to Day 1 to 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01713348"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Difference in time in range (70-180 mg/dL, 3.9 to 10.0 mmol/L) intervention arm compared to control arm.", 
                "measure": "Difference in time in range", 
                "safety_issue": "No", 
                "time_frame": "Days 86 to 100 compared to day 1 to 15"
            }, 
            {
                "description": "Number of excursions and duration (number of hours) of hypoglycaemia events per day.", 
                "measure": "Hypoglycaemia", 
                "safety_issue": "No", 
                "time_frame": "Day 86 to 100 compared to day 1 to 15"
            }, 
            {
                "description": "Number of excursions and duration (number of hours) of hyperglycaemia events per day.", 
                "measure": "Hyperglycaemia", 
                "safety_issue": "No", 
                "time_frame": "Day 86 to 100 compared to day 1 to 15"
            }, 
            {
                "description": "Time outside glucose range (70-180 mg/dL, 3.9 to 10.0 mmol/L).", 
                "measure": "Time in Hypoglycaemia and Hyperglycaemia", 
                "safety_issue": "No", 
                "time_frame": "Day 86 to 100 compared to day 1 to 15"
            }, 
            {
                "description": "Mean Glucose", 
                "measure": "Mean Glucose", 
                "safety_issue": "No", 
                "time_frame": "Day 86 to 100 compared to day 1 to 15"
            }, 
            {
                "description": "Any changes in glycaemic control or variability", 
                "measure": "Glycaemic variability", 
                "safety_issue": "No", 
                "time_frame": "Day 86 to 100 compared to day 1 to 15"
            }, 
            {
                "description": "Any changes or differences in frequency of blood glucose testing", 
                "measure": "Frequency of blood glucose testing", 
                "safety_issue": "No", 
                "time_frame": "Day 86 to 100 compared to day 1 to 15"
            }, 
            {
                "description": "Laboratory blood chemistry tests to provide a measure of glycaemic control.", 
                "measure": "HbA1c, fructosamine and lipid profiles", 
                "safety_issue": "No", 
                "time_frame": "Day 100 compared to day 1"
            }, 
            {
                "description": "Scores for the for the Diabetes Treatment Satisfaction Questionnaire (DTSQ),status version and changes version compared for each study group.", 
                "measure": "DTSQ", 
                "safety_issue": "No", 
                "time_frame": "Day 86 compared to day 1"
            }
        ], 
        "source": "Abbott Diabetes Care", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abbott Diabetes Care", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}